MARTINSRIED/MUNICH, Germany, June 2 /PRNewswire-FirstCall/ -- WALTHAM,
Mass. and PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC;
TecDAX index; Nasdaq: GPCB) today announced that the Company will give a
corporate presentation at three upcoming conferences in the U.S. -- the
Pacific Growth Equities Life Sciences Growth Conference in San Francisco,
CA; the Goldman Sachs 27th Annual Global Healthcare Conference in Dana
Point, CA; and the Fifth Annual Needham & Company Biotechnology and Medical
Technology Conference in New York, NY.
The Company's presentation at the Pacific Growth conference will take
place on Monday, June 12, 2006 at 8 AM PDT/11 AM EDT/5 PM CET.
The presentation at the Goldman Sachs conference will take place on
Tuesday, June 13, 2006 at 8:05 AM PDT/11:05 AM EDT/5:05 PM CET.
The presentation at Needham & Company conference will take place on
Thursday, June 15, 2006 at 11 AM EDT/5 PM CET.
All three of these company presentations will be webcast live and will
be accessible through the GPC Biotech Web site at
http://www.gpc-biotech.com. A replay will also be available via the Web
site.
GPC Biotech AG is a biopharmaceutical company discovering and
developing new anticancer drugs. The Company's lead product candidate --
satraplatin -- has achieved target enrollment in a Phase 3 registrational
trial as a second-line chemotherapy treatment in hormone-refractory
prostate cancer. The U.S. FDA has granted fast track designation to
satraplatin for this indication, and GPC Biotech has begun the rolling NDA
submission process for this compound. GPC Biotech is also developing a
monoclonal antibody with a novel mechanism-of-action against a variety of
lymphoid tumors, currently in Phase 1 clinical development, and has ongoing
drug development and discovery programs that leverage its expertise in
kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham,
Massachusetts and Princeton, New Jersey. For additional information, please
visit the Company's Web site at http://www.gpc-biotech.com.
For further information, please contact:
GPC Biotech AG
Martin Braendle
Associate Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.:
Laurie Doyle
Associate Director, Investor Relations & Corporate Communications
Phone: +1 781-890-9007 X267
usinvestors@gpc-biotech.com
SOURCE GPC Biotech AG
 back to top
Related links:
http://www.gpc-biotech.com/
CONTACT:
Martin Braendle, Associate Director, Investor
Relations & Corporate Communications, +49 (0)89 8565-2693,
ir@gpc-biotech.com, or In the U.S.: Laurie Doyle, Associate
Director, Investor Relations & Corporate Communications,
+1-781-890-9007 X267, usinvestors@gpc-biotech.com, both of GPC
Biotech AG
|
